Project Grant R01CA295454
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$442K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will support research to investigate the role of natural killer (NK) cells in melanoma tumor invasion and immune evasion. The $217,863 award to the University of Colorado-Denver will use advanced techniques such as multiplexed immunohistochemistry, single-cell spatial transcriptomics, and patient-derived organoid models to evaluate how the KIR/HLA axis impacts the function of decidual-like NK...
This federal Project Grant award, R21CA297650, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $198,103 award will fund research by New York University School of Medicine to investigate the role of the immune microenvironment in melanoma bone metastasis. Specifically, the research aims to define the mechanisms melanoma cells use to colonize the skeleton and modify the bone microenvironment, as well as the interplay between tumor,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $312,892 to Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The research aims to better understand how ILC3s can create immunosuppressive conditions that limit the effectiveness of immune checkpoint inhibitor (ICI) therapies for advanced melanoma. By defining the function of ILC3s in the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Dartmouth-Hitchcock Clinic is focused on understanding the role of melanocyte PD-L1 expression in modulating the immune response to UV-induced melanoma. The $635,946 award, with a performance period from July 2024 to June 2029, will support research using an autochthonous mouse melanoma model to investigate how UV radiation-induced interferon-I signaling and tumor inflammatory memory...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $395,509 to Beth Israel Deaconess Medical Center, Inc. to conduct research into targeting the SKP2 axis for anti-melanoma therapy. The research aims to 1) define the molecular mechanisms by which the dysregulated RNF12-SKP2 E3 ligase cascade promotes melanoma tumorigenesis, and 2) investigate how SKP2-mediated HHIP protein degradation plays an essential role in melanomagenesis. The...
This Project Grant award from the National Cancer Institute (NCI), under the federal grant program "Cancer Cause and Prevention Research" (CFDA 93.393), provides $442,089 to Yale University to conduct research aimed at defining the key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and identifying pathways that can restore viability in MTAP-deleted cancer cells. The research project, scheduled to run from January 1, 2025 to November 30, 2029, will...
This $1,824,208 Project Grant award was provided by the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) federal grant program. The award supports research focused on understanding the molecular mechanisms that govern melanoma cell plasticity and differentiation, and how this impacts tumor progression and immune evasion. The key research activities include: Defining the molecular mechanisms by which the transcription factor TFEB regulates melanoma cell phenotype...
This $3,510,000 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to study novel mechanisms underlying the regulation and function of the key unfolded protein response (UPR) signaling component ATF4, and its impact on melanoma metastasis and resistance to therapy. The research aims to elucidate (1) how aging affects metabolic signaling and ATF4-dependent pro-...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,024,967.00 to Celdara Medical, LLC for the development of CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The project aims to advance CM-HZ01 through Investigational New Drug (IND) filing for clinical testing in metastatic melanoma patients, a condition with limited effective treatment options. The funding supports research to engineer a selective...
This $177,058 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to discover and optimize novel anti-mitotic agents for the treatment of metastatic melanoma. The grant aims to develop fused heterocyclic pyrazine (FHP) based tubulin inhibitors that can overcome drug resistance and reduce toxicity associated with current treatments. The research involves three key...